Regeneron Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Regeneron Pharmaceuticals Inc Unternehmen

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Unternehmensinformationen

Unternehmens-codeREGN

Name des UnternehmensRegeneron Pharmaceuticals Inc

IPO-datumApr 02, 1991

Gegründet am1988

CEODr. Leonard S. Schleifer, M.D., Ph.D

Anzahl der mitarbeiter15106

WertpapierartOrdinary Share

GeschäftsjahresendeApr 02

Addresse777 Old Saw Mill River Road

StadtTARRYTOWN

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl10591

Telefon17813705000

Websitehttps://www.regeneron.com/

Unternehmens-codeREGN

IPO-datumApr 02, 1991

Gegründet am1988

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.45K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.40K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

Mr. George L. Sing

Independent Director

29.90K

+0.56%

Mr. Arthur F. (Art) Ryan

Independent Director

17.67K

+0.95%

Mr. Christopher R. Fenimore

Chief Financial Officer, Senior Vice President - Finance

16.35K

+6.24%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.45K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.40K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

Umsatzaufteilung

Währung: USDUpdate-Zeit: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

EYLEA

4.77B

33.57%

Sanofi

4.53B

31.91%

Bayer

1.50B

10.55%

EYLEA HD

1.20B

8.46%

Libtayo

787.30M

5.54%

Other

1.42B

9.97%

Keine Daten

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

EYLEA

4.77B

33.57%

Sanofi

4.53B

31.91%

Bayer

1.50B

10.55%

EYLEA HD

1.20B

8.46%

Libtayo

787.30M

5.54%

Other

1.42B

9.97%

Aktionäre

Update-Zeit: Fri, Feb 21

Aktionärsstatistik

Art

Aktionärsstatistik

Aktionäre

Anteil

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.30%

JP Morgan Asset Management

4.88%

State Street Global Advisors (US)

4.49%

Other

69.32%

Aktionärsstatistik

Aktionäre

Anteil

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.30%

JP Morgan Asset Management

4.88%

State Street Global Advisors (US)

4.49%

Other

69.32%

Art

Aktionäre

Anteil

Investment Advisor

47.88%

Investment Advisor/Hedge Fund

33.06%

Research Firm

2.77%

Pension Fund

2.59%

Bank and Trust

2.16%

Hedge Fund

2.07%

Individual Investor

1.66%

Sovereign Wealth Fund

1.15%

Insurance Company

0.08%

Other

6.57%

Institutionelle Beteiligung

Update-Zeit: Sun, Jan 19

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

2516

100.27M

93.27%

-268.91K

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

2022Q4

2333

99.78M

93.16%

-1.62M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

9.24M

8.59%

-32.55K

-0.35%

Dec 31, 2024

Fidelity Management & Research Company LLC

7.97M

7.41%

-2.08M

-20.68%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.70M

5.3%

+193.71K

+3.52%

Dec 31, 2024

JP Morgan Asset Management

5.24M

4.88%

-524.97K

-9.10%

Dec 31, 2024

State Street Global Advisors (US)

4.83M

4.49%

-70.17K

-1.43%

Dec 31, 2024

Capital International Investors

4.74M

4.41%

+1.39M

+41.55%

Dec 31, 2024

Capital World Investors

2.78M

2.58%

-1.52M

-35.35%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.43M

2.26%

+155.37K

+6.84%

Dec 31, 2024

Dodge & Cox

2.32M

2.16%

+9.38K

+0.41%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

2.24M

2.08%

+29.93K

+1.36%

Feb 28, 2025

Verbundene ETFs

Update-Zeit: Sun, Apr 6

Name

Anteil

Tema Neuroscience and Mental Health ETF

7.56%

Invesco Nasdaq Biotechnology ETF

7.22%

ProShares Ultra Nasdaq Biotechnology

6.8%

Simplify Health Care ETF

6.73%

iShares Biotechnology ETF

6.22%

VanEck Biotech ETF

4.94%

Invesco Biotechnology & Genome ETF

4.65%

iShares Genomics Immunology and Healthcare ETF

4%

Franklin Genomic Advancements ETF

3.51%

Invesco QQQ Low Volatility ETF

3.35%

Tema Neuroscience and Mental Health ETF

Anteil7.56%

Invesco Nasdaq Biotechnology ETF

Anteil7.22%

ProShares Ultra Nasdaq Biotechnology

Anteil6.8%

Simplify Health Care ETF

Anteil6.73%

iShares Biotechnology ETF

Anteil6.22%

VanEck Biotech ETF

Anteil4.94%

Invesco Biotechnology & Genome ETF

Anteil4.65%

iShares Genomics Immunology and Healthcare ETF

Anteil4%

Franklin Genomic Advancements ETF

Anteil3.51%

Invesco QQQ Low Volatility ETF

Anteil3.35%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

Regeneron Pharmaceuticals Inc

557.910USD

Regeneron Pharmaceuticals Inc

557.910

Übersicht

Unternehmen